Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37524953

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Nat Med
Publication date
2023 Aug
First author
Shah MA

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Shah MA
      type
      Author
    2. name
      Shitara K
      type
      Author
    3. name
      Ajani JA
      type
      Author
    4. name
      Bang YJ
      type
      Author
    5. name
      Enzinger P
      type
      Author
    6. name
      Ilson D
      type
      Author
    7. name
      Lordick F
      type
      Author
    8. name
      Van Cutsem E
      type
      Author
    9. name
      Gallego Plazas J
      type
      Author
    10. name
      Huang J
      type
      Author
    11. name
      Shen L
      type
      Author
    12. name
      Oh SC
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Shah MA
      type
      Author
    2. name
      Shitara K
      type
      Author
    3. name
      Ajani JA
      type
      Author
    4. name
      Bang YJ
      type
      Author
    5. name
      Enzinger P
      type
      Author
    6. name
      Ilson D
      type
      Author
    7. name
      Lordick F
      type
      Author
    8. name
      Van Cutsem E
      type
      Author
    9. name
      Gallego Plazas J
      type
      Author
    10. name
      Huang J
      type
      Author
    11. name
      Shen L
      type
      Author
    12. name
      Oh SC
      type
      Author
    bibliography ids
    1. nci-bib-a36d4200e6d21246a846522a
    book metadata
    content sha256
    ffca57960a6b63e345481c7034f21f47ca0a4b2d3609bbe6eb18b15ccdf38de2
    document type
    citation
    dois
    1. 10.1038/s41591-023-02465-7
    electronic publication date
    display
    2023 Jul 31
    precision
    day
    year
    2023
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:37524953
    immutable id
    pubmed:37524953@ffca57960a6b63e345481c7034f21f47ca0a4b2d3609bbe6eb18b15ccdf38de2
    journal
    abbreviation
    Nat Med
    issn electronic
    1546-170X
    issn print
    1078-8956
    issue
    8
    name
    Nature medicine
    nlm unique id
    9502015
    pages
    2133-2141
    volume
    29
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      37524953
      provenance
      batch id
      5329a5d0877ee70ecd11
      provider
      NCBI PubMed ESummary
      record sha256
      134bd7c00e15117322841401c06081d2d9759ab03f27009b8deb591d49fbc575
      response sha256
      bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
      retrieved at
      2026-09-09T23:48:15.763286+00:00
      publication date
      display
      2023 Aug
      precision
      month
      year
      2023
      publication types
      1. Clinical Trial, Phase III
      2. Journal Article
      3. Randomized Controlled Trial
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/37524953/
      title
      Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.

      Preserved source evidence · Not medical advice